Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Biotechnology

Healthcare
$43.11 +5.87%

+$4.49 today

Market cap
$6.09B
Beta
1.27
P/E (TTM)
-38.4
EPS (TTM)
-$2.11
52W Low $14.30High $82.48

Volume 2.42M

Average 1.82M

ARWR Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR

Capital Expenditures · Q4 FY2026 · quarter ended Sep 2026

Capital expenditures declines year over year

Q4 FY2026 capital expenditures of $3.43M (cash outflow) fell 54.2% year over year, behind the -47.1% change in trailing-twelve-month capital expenditures. Sequentially, it fell 11.1% from the prior quarter. Over 3 fiscal years it compounded at -59.2% a year.

Context

  • Capital expenditures amounted to 2.7% of revenue in FY2026, unchanged from a year earlier.
  • Capital expenditures grew in size in 0 of the last 3 fiscal years.
  • FY2026 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -54.2% toward the trailing-twelve-month pace of -47.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$3.43M-11.1% QoQ
Last fiscal yearSep 2026
-$12M-47.1% YoY
LTMSep 2026
-$12M-47.1% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-54.2%——
1 year-47.1%——
3-year CAGR-59.2%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2026
(12M) USD
Year-over-year change
+47.1%

Capital Expenditures vs competitors

How ARWR compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -47.1% is the lowest of 6, against a peer median of +29.1%.
  • Capital expenditures amounts to 2.7% of revenue for ARWR, versus a peer median of 4.5%.
ARWR Competitors
Capital Expenditures for ARWR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$91.95M USD+151.6%-6.6%1.9%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$71.85M USD+29.1%+36.8%7.5%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$12M USD-47.1%-59.2%2.7%
WVEWave Life Sciences Ltd.LTM Mar 2026$981.99K USD+43.1%-19.2%1.4%
PRQRProQR Therapeutics N.V.LTM Mar 2026€955.79K EUR+5.0%+11.4%7.1%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$318.66K USD-41.5%-69.0%0.7%
SLNSilence Therapeutics plcLTM Mar 2026$106K USD—-53.4%11.5%
Peer median (excluding ARWR) —+29.1%-12.9%4.5%

Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Net Income(176.49M)(209.28M)(609.69M)30.11M(717.13M)
Depreciation & Amortization10.42M12.49M18.6M23.93M26.62M
Deferred Income Tax00000
Stock-Based Compensation120.89M78.13M73.97M63.37M68.15M
Change in Working Capital(98.29M)(51.55M)25.09M(18.24M)60.9M
Accounts Receivables8.85M1.41M0(56.97M)(3.29M)
Inventory0000(9.08M)
Accounts Payables(6.59M)33M(5.54M)6.29M12.48M
Other Working Capital(100.55M)(85.96M)30.63M32.45M60.78M
Other Non-Cash Items7.34M16.31M29.19M80.38M289.52M
Operating Cash Flow(136.13M)(153.89M)(462.85M)179.55M(271.95M)
Capital Expenditures(52.78M)(176.74M)(141.47M)(22.67M)(12M)
Acquisitions (Net)00000
Purchases of Investments(223.39M)(246.14M)(720.95M)(796.26M)(1.14B)
Sales of Investments270.75M326.72M442.34M689.63M695.23M
Other Investing Activities0000(215M)
Investing Cash Flow(5.42M)(96.16M)(420.07M)(129.29M)(670.48M)
Debt Repayment00392M(191.37M)578.52M
Common Stock Issued5.19M3.05M431.65M270.37M305.41M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities60M250M46.87M(5M)(107.12M)
Financing Cash Flow65.19M253.05M870.52M74.01M776.82M
Effect of Forex Changes(67K)(122K)4.2M(401K)1.8M
Net Change in Cash(76.43M)2.89M(8.21M)123.86M(163.81M)
Free Cash Flow(188.91M)(330.63M)(604.32M)156.89M(283.94M)

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Intrinsic Alpha fair value

Locked

Current Price

$43.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.